ViRexx collaborates with Canada’s NINT and DRDC Suffield

June 11, 2007 — ViRexx Medical Corp. of Edmonton, Alberta, a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, has signed collaboration agreements with the National Research Council (NRC) Canada’s National Institute for Nanotechnology (NINT) and Defence Research and Development Canada Suffield (DRDC Suffield) with networking and financial contribution from NRC-Industrial Research Assistance Program (IRAP).

Researchers at NINT will study the physical characteristics, as well as immunological and nanoparticle forming properties of a Chimigen Vaccine, produced using ViRexx’s proprietary Chimigen Vaccine platform technology. Meanwhile, researchers at DRDC Suffield continue to study Chimigen for biodefense applications.

“These research collaborations were supported through network and financial contribution from NRC-IRAP which provide us with the opportunity to explore multiple uses of our Chimigen . . . and establish its efficacy as an adaptable platform technology in nanoparticle and biodefence applications,” said Peter Smetek, interim CEO and Chairman of the Board of Directors of ViRexx Medical Corp.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.